ADAR1 Capital Management, LLC - Jun 28, 2024 Form 3/A Insider Report for Acasti Pharma Inc. (ACST)

Role
10%+ Owner
Signature
ADAR1 Capital Management, LLC, By /s/ Daniel Schneeberger, Manager
Stock symbol
ACST
Transactions as of
Jun 28, 2024
Transactions value $
$0
Form type
3/A
Date filed
7/11/2024, 11:16 AM
Date Of Original Report
Jul 9, 2024
Next filing
Jul 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACST Class A Common Stock 960K Jun 28, 2024 By: ADAR1 Partners F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACST Common Warrant (Common Stock) Jun 28, 2024 Common Stock 1.27M $3.00 By: ADAR1 Partners F1, F2, F3, F5
holding ACST Pre-Paid Warrant (Common Stock) Jun 28, 2024 Common Stock 914K $0.00 By: ADAR1 Partners F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP ("ADAR1 Partners").
F2 ADAR1 Capital Management, LLC ("ADAR1 Capital"), an entity owned and controlled by Dr. Daniel Schneeberger, owns voting and investment control with respect to the shares held by ADAR1 Partners, LP. Because of the relationship between ADAR1 Partners and ADAR1 Capital, ADAR1 Capital may be deemed to beneficially own the shares held directly by ADAR1 Partners.
F3 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
F4 Pursuant to a Pre-Funded Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 913,631 shares of Issuer's Common Stock, exercisable until fully filled.
F5 Pursuant to a Common Stock Purchase Warrant, ADAR1 Partners may purchase up to 1,268,195 of Issuer's Common Stock.